CPBIO Holding Co (HKSE:03839) Research & Development: HK$0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:03839 CPBIO Holding Co Ltd HKSE:03839
71 GF Score
Price HK$9.20
GF Value HK$4.36
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CPBIO Holding Co Research & Development?

CPBIO Holding Co HKSE:03839 71 Research & Development is HK$0 Mil as of Dec. 2025. GuruFocus rates HKSE:03839 with a GF Score™ of 71/100 and a GF Value™ of HK$4.36 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. CPBIO Holding Co's Research & Development for the three months ended in Dec. 2025 was HK$0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0 Mil.

CPBIO Holding Co  (HKSE:03839) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

CPBIO Holding Co Research & Development Related Terms

CPBIO Holding Co Research & Development Historical Data

* Premium members only.

The historical data trend for CPBIO Holding Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CPBIO Holding Co Research & Development Chart

CPBIO Holding Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CPBIO Holding Co Quarterly Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HKSE:03839
71GF Score
CPBIO Holding Co Ltd HKSE:03839
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CPBIO Holding Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$0 Mil mean?
CPBIO Holding Co (HKSE:03839) has a Research & Development of HK$0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on CPBIO Holding Co and its competitors.
Is CPBIO Holding Co's Research & Development too high?
CPBIO Holding Co's current Research & Development is HK$0 Mil. Overall, CPBIO Holding Co has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CPBIO Holding Co's Research & Development compare to ZTS?
CPBIO Holding Co's Research & Development of HK$0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on CPBIO Holding Co and its competitors. CPBIO Holding Co's current Research & Development is HK$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CPBIO Holding Co stock overvalued right now?
Based on GuruFocus' analysis, CPBIO Holding Co (HKSE:03839) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$4.36, compared to a current price of HK$9.20 — trading 110.9% above its estimated fair value. The current Research & Development is HK$0 Mil. CPBIO Holding Co's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For CPBIO Holding Co (HKSE:03839), the current Research & Development is HK$0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CPBIO Holding Co (HKSE:03839) Overvalued in 2026?

Based on GuruFocus' analysis, CPBIO Holding Co stock appears to be overvalued. The current stock price of HK$9.20 is trading 110.9% above its estimated GF Value™ of HK$4.36. GuruFocus considers CPBIO Holding Co to be Significantly Overvalued.

Key valuation signals for HKSE:03839:

  • Research & Development: HK$0 Mil
  • GF Value™: HK$4.36 vs. price of HK$9.20 (110.9% above fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the HKSE:03839 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CPBIO Holding Co Business Description

Address 16 Harcourt Road, 21st Floor, Far East Finance Centre, Central, Hong Kong, HKG
Chia Tai Enterprises International Ltd is engaged in the manufacture and sale of animal health products and chlortetracycline (CTC). The group has two reportable segments: Biotech Business and Investment Business. The Biotech Business segment is involved in the manufacture and/or sale of animal health products and chlortetracycline. The Investment Business segment is engaged in the trading of machinery and the manufacture and sale of automotive parts through the group's joint ventures and associates. It generates the majority of its revenue from the Biotech Business segment. Its geographical segments are Mainland China, which generates key revenue, Asia Pacific (excluding mainland China), the Americas, Europe, and Others.
71GF Score

Get the complete analysis for HKSE:03839

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$9.20
Price
HK$4.36
GF Value